Prices delayed by at least 15 minutes | Print
Xenon Pharmaceuticals (XENE)
Common SharesOpen
$41.49
Previous close
$41.49
Trade high
$41.99
Volume
393,800
Year high
$50.99
Year low
$27.99
Dividend yield
-
Market capitalisation
$3.14 bn
P/E ratio
-
ISIN
CA98420N1050
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Share price
Company profile
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.